DIA454.26-2.79 -0.61%
SPX6,466.78-35.30 -0.54%
IXIC21,651.83-55.86 -0.26%

ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

PR Newswire·09/02/2025 05:41:00
Listen to the news

LOS ANGELES, Sept. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the federal securities laws.

Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ("IPO") conducted on or about February 2, 2024 and/or between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period"), are encouraged to contact the firm before September 19, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Alto Neuroscience led investors to believe that ALTO-100 was more effective in treating major depressive disorder ("MDD") than it actually was. The Company overstated its business and financial prospects. Based on these facts, the Company's public statements were false and materially misleading throughout the offering period. When the market learned the truth about Alto Neuroscience, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/anro-investors-have-opportunity-to-lead-alto-neuroscience-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302543390.html

SOURCE The Schall Law Firm

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.